Toutes les études
RecrutementPHASE3INTERVENTIONNEL

Essai de plateforme adaptative multifactorielle, intégré et randomisé pour la pneumonie acquise en communauté

The REMAP-CAP study is looking at the best ways to treat adults who are very unwell with lung infections such as severe pneumonia, the flu, or COVID-19, and need care in an intensive care unit (ICU). It's a special type of study that allows doctors to test many different treatments at the same time to see which ones are most effective. This flexible design means the study can quickly adapt to new information, helping doctors make better decisions about care. The goal is to improve how patients recover from these serious illnesses. This study can also quickly adapt to new health crises, like a pandemic, to find treatments for new viruses.

En un coup d'œil

Statut
Recrutement
Phase
PHASE3
Sponsor
UMC Utrecht
Objectif d'inscription
20,000
Démarrer
11 Apr 2016
Achèvement estimé
01 Feb 2028

De quoi parle cette étude ?

When someone is very ill with a serious lung infection, like severe pneumonia, the flu, or COVID-19, they often need to be looked after in an intensive care unit (ICU). In the ICU, doctors use many different treatments to help patients get better and fight off the infection. While doctors know many treatments are helpful, it's not always clear which combination works best for different people.

This study, called REMAP-CAP, is designed to help doctors figure out the most effective ways to treat these severe lung infections. It's a clever type of study that can test many different treatments all at once. What's more, it's 'adaptive', meaning it can learn from the patients already in the study. This helps the study identify promising treatments faster and direct new patients towards the treatments that seem to be working best.

The main aim is to improve how patients recover from these serious lung infections. It also acts like a flexible research 'platform' that can quickly start looking for treatments if a new widespread illness, like a pandemic, emerges. This means it can rapidly respond to new health challenges and continue to find the best care for patients.

Points clés

  • Targets severe lung infections like pneumonia, flu, and COVID-19.
  • Aims to find the best combinations of existing treatments.
  • Can test many treatments at once and adapt quickly.
  • Helps improve care for very unwell patients in intensive care.
  • Can rapidly respond to new health crises, like pandemics.

Qui peut être éligible ?

Generally, to join the main REMAP-CAP study, you need to be an adult (18 or over) admitted to an intensive care unit (ICU) because of a severe lung infection, like pneumonia, within two days of getting to the hospital. Your doctors would have seen signs of a lung infection and scans showing changes in your lungs. You would also need support for your organs, such as help with breathing or medication to support your blood pressure.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Avez-vous 18 ans ou plus ?
  2. Have you been admitted to intensive care for a severe lung infection?
  3. Did you come to the ICU within 48 hours of being admitted to the hospital?
  4. Do you need support for breathing or blood pressure in the ICU?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you are asked to join this study, it means your doctors believe you could benefit from it. You would continue to receive the best care for your condition, and the study would involve trying different combinations of existing treatments. This includes various medicines for infection, inflammation, or to prevent blood clots. There are no extra hospital visits or special appointments as part of the study; all monitoring would happen as part of your usual intensive care. The study aims to understand the best treatment approaches and would continue for as long as you need intensive care, with doctors monitoring your progress carefully.

Risques et avantages potentiels

The main benefit of taking part is that you would receive care based on the latest knowledge and could potentially receive a treatment combination that is more effective for your condition. As the study uses existing, approved medications, the risks are generally similar to those you would face with standard intensive care. However, any medication can have side effects, and your doctors would monitor you closely for these. You, or your legal representative, have the right to withdraw from the study at any time without affecting your medical care.

Locations (408)

  • University of Florida
    Code postal vérifié
    Jacksonville, États-Unis· Recrutement
  • Augusta University
    Code postal vérifié
    Augusta, United States· Pas encore en recrutement
  • University of Illinois Health
    Code postal vérifié
    Chicago, États-Unis· Recrutement
  • Tulane Medical Center
    Code postal vérifié
    Nouvelle-Orléans, États-Unis· Pas encore en recrutement
  • University of Michigan
    Code postal vérifié
    Ann Arbor, États-Unis· Recrutement
  • Memorial Sloan Kettering Cancer Center
    Code postal vérifié
    New York, États-Unis· Recrutement
  • Wake Forest Baptist Health
    Code postal vérifié
    Winston-Salem, United States· Pas encore en recrutement
  • The Ohio State University Wexner Medical Center
    Code postal vérifié
    Columbus, États-Unis· Recrutement
  • Oregon Health and Science University
    Code postal vérifié
    Portland, États-Unis· Recrutement
  • University of Pittsburgh Medical Centre
    Code postal vérifié
    Pittsburgh, United States· Recrutement
  • Brown University - Rhode Island Hospital
    Code postal vérifié
    Providence, United States· Pas encore en recrutement
  • Canberra Hospital
    Code postal vérifié
    Canberra, Australia· Recrutement

Questions fréquentes

What kind of infections does this study look at?

It looks at serious lung infections like pneumonia, the flu, and severe COVID-19 that require intensive care.

Why is this study different from others?

It can test many treatments at once and adapt quickly, learning from patients already in the study to find better treatments faster.

Will I get special treatment if I join?

You will receive the best possible care, and the study helps doctors choose the most effective combination of existing treatments for you.

Will I have to pay for anything?

No, all care and treatments related to the study are part of your hospital care and involve no extra cost to you.

Puis-je quitter l'étude si je change d'avis ?

Yes, you or your family can decide to withdraw from the study at any time. Your medical care will not be affected.

Comment en savoir plus

Cameron Green, MSc

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "Randomized, Embedded, Multifactorial Adaptive Platform Trial… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.